Literature DB >> 35283692

National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017-2019.

Jill Tarasuk1, Jingxuan Zhang1, Anaïs Lemyre1, François Cholette2, Maggie Bryson1, Dana Paquette1.   

Abstract

Background: The Tracks survey of people who inject drugs (PWID) collected data in 14 sentinel sites across Canada (2017-2019). Objective: To describe the prevalence of human immunodeficiency virus (HIV) and hepatitis C and associated risk behaviours and to examine trends over time.
Methods: Information regarding socio-demographics, social determinants of health, use of prevention services and testing, drug use, risk behaviours, and HIV and hepatitis C testing, care and treatment was collected through interviewer-administered questionnaires. Biological samples were tested for HIV, hepatitis C antibodies and hepatitis C ribonucleic acid (RNA). Descriptive statistics were calculated and trends over time were assessed.
Results: Of the 2,383 participants, 65.6% were cisgender male, 42.2% were Indigenous, 48.0% completed some high school or less, 62.6% lived in unstable housing and 75.7% had ever been incarcerated. Average age was 40.1 years. The majority experienced stigma and discrimination (88.7%) and physical, sexual and/or emotional abuse in childhood (85.0%) or with a sexual partner (75.9%). The majority reported use of a needle/syringe distribution program (90.1%) and tested for HIV (90.5%) and hepatitis C (90.9%).Among participants who had ever had sex, the majority (59.2%) reported inconsistent condom use during vaginal and/or anal sex with a casual sex partner. Prevalence of HIV was 10.3% (82.9% were aware of infection status) and many (36.9%) were hepatitis C RNA-positive (50.1% were aware of infection status).Most surveillance indicators remained relatively stable from Phase 1 to Phase 4. Changes were found in substances used, and improvements were noted related to HIV and hepatitis C prevalence and care cascade indicators.
Conclusion: Many PWID in Canada were living in unstable housing and experienced high levels of stigma and discrimination. Prevalence of HIV and hepatitis C was high in some areas. These findings contribute to the evidence base used to inform targeted prevention and control measures.

Entities:  

Keywords:  HIV; care and treatment; drug use; hepatitis C; infection status; injecting behaviours; overdose; people who inject drugs; sexual risk practices; testing

Year:  2020        PMID: 35283692      PMCID: PMC8868043          DOI: 10.14745/ccdr.v46i05a07

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


  4 in total

1.  The Cedar Project: risk factors for transition to injection drug use among young, urban Aboriginal people.

Authors:  Cari L Miller; Margo E Pearce; Akm Moniruzzaman; Vicky Thomas; Wayne Christian; Martin T Schechter; Patricia M Spittal
Journal:  CMAJ       Date:  2011-06-13       Impact factor: 8.262

2.  Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: growth mixture modeling using data from prospective cohort studies.

Authors:  Huiru Dong; Kanna Hayashi; Joel Singer; Michael John Milloy; Kora DeBeck; Evan Wood; Thomas Kerr
Journal:  Addiction       Date:  2019-08-16       Impact factor: 6.526

3.  Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.

Authors:  M Eugenia Socías; Lianping Ti; Evan Wood; Ekaterina Nosova; Mark Hull; Kanna Hayashi; Kora Debeck; M-J Milloy
Journal:  Liver Int       Date:  2019-02-24       Impact factor: 5.828

4.  Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.

Authors:  Louisa Degenhardt; Fiona Charlson; Jeff Stanaway; Sarah Larney; Lily T Alexander; Matthew Hickman; Benjamin Cowie; Wayne D Hall; John Strang; Harvey Whiteford; Theo Vos
Journal:  Lancet Infect Dis       Date:  2016-09-21       Impact factor: 25.071

  4 in total
  4 in total

1.  Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario.

Authors:  Mia J Biondi; Grishma Hirode; Camelia Capraru; Aaron Vanderhoff; Joel Karkada; Brett Wolfson-Stofko; David Smookler; Steven M Friedman; Kathy Bates; Tony Mazzulli; Joshua V Juan; Hemant Shah; Bettina E Hansen; Jordan J Feld; Harry LA Janssen
Journal:  Can Liver J       Date:  2022-08-16

2.  The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment.

Authors:  Lillian Lourenço; Marian Kelly; Jill Tarasuk; Kyla Stairs; Maggie Bryson; Nashira Popovic; Josephine Aho
Journal:  Can Commun Dis Rep       Date:  2021-12-09

3.  Evaluation of the bioMérieux VIDAS HIV Duo Quick and Anti-HCV assays for dried blood spot based serosurveillance.

Authors:  François Cholette; Braedy Farmer; Olga Balakireva; Daria Pavlova; Anna Lopatenko; Iryna Chukhalova; Svitlana Bargan; Sharmistha Mishra; Marissa Becker; Emma R Lee; John Kim; Paul Sandstrom
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

4.  Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada.

Authors:  Carla Osiowy; Ken Swidinsky; Sarah Haylock-Jacobs; Matthew D Sadler; Scott Fung; David Wong; Gerald Y Minuk; Karen E Doucette; Philip Wong; Edward Tam; Curtis Cooper; Alnoor Ramji; Mang Ma; Carmine Nudo; Keith Tsoi; Carla S Coffin
Journal:  JHEP Rep       Date:  2022-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.